Healthcare Services

Influenza Diagnostic Market Expected To Witness Revenue Growth Toward $4.18 Billion By 2030

May 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Increase In Market Value Is Predicted For The Influenza Diagnostic Market During The 2026–2030 Period?

The influenza diagnostic market has recently experienced significant expansion. This market is projected to expand from $2.87 billion in 2025 to $3.1 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.3%. The historical expansion of this market stems from several factors, including seasonal influenza outbreaks, the broad adoption of rapid antigen tests, the development of hospital laboratory infrastructure, governmental influenza surveillance programs, and a heightened understanding of the importance of early flu diagnosis.

The influenza diagnostic market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $4.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This projected growth during the forecast period can be attributed to several factors, including the increasing occurrence of influenza epidemics, a heightened need for precise molecular diagnostics, the proliferation of point-of-care testing facilities, enhanced public health readiness initiatives, and innovations in rapid diagnostic assays. Key trends anticipated during the forecast period encompass an escalating demand for swift influenza testing, a greater embrace of molecular diagnostic techniques, an increasing inclination towards point-of-care flu diagnostics, the broadening of seasonal and pandemic surveillance testing, and ongoing enhancements in test sensitivity and specificity.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3237&type=smp

What Core Drivers Are Transforming The Influenza Diagnostic Market?

The influenza diagnostic market is anticipated to expand due to the rising financial investment in influenza diagnostics research. This funding represents financial contributions from government bodies, institutions, and various organizations to back scientific studies focused on creating, enhancing, and validating techniques and technologies for identifying influenza viruses. This increased investment in influenza research stems from insights gained during the COVID-19 pandemic and worries about potential future respiratory outbreaks, given that health authorities understand the crucial role of quick and precise diagnostic tools in preventing broad transmission and facilitating prompt public health responses. Elevated research funding aids the creation and market introduction of sophisticated testing technologies, molecular assays, point-of-care instruments, and refined laboratory protocols, all of which allow for quicker and more accurate identification of influenza strains in medical environments. As an illustration, in October 2024, the Department of Health and Aged Care, an Australia-based governmental entity overseeing health research, funding, promotion, and regulation, reported that the Australian Government is dedicating $95 million to address avian influenza, thereby safeguarding agriculture, wildlife, and the economy. Consequently, the enhanced funding for influenza diagnostics research is propelling the expansion of the influenza diagnostic market.

How Is The Influenza Diagnostic Market Distributed Across Key Segments?

The influenza diagnostic market covered in this report is segmented –

1) By Traditional Diagnostic Tests: Rapid Influenza Diagnostic Tests (RIDT), Viral Culture, DFA, Serological Assays, Other Traditional Diagnostic Tests

2) By Molecular Diagnostic Tests: Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification Tests (INAAT), Loop Mediated Isothermal Based Amplification Assays, Transcription Mediated Isothermal Based Amplification Assays, Other Isothermal Nucleic Acid Amplification Tests, Other Molecular Diagnostic Tests

3) By End User: Hospitals And Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Other End Users

Subsegments:

1) By Rapid Influenza Diagnostic Tests (RIDT): Immunoassay-based Tests, Lateral Flow Assays, Enzyme Immunoassays (EIA)

2) By Viral Culture: Cell Culture, Egg-based Culture

3) By Serological Assays: Hemagglutination Inhibition (HI) Assay, Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting Assay

4) By Other Traditional Diagnostic Tests: Polymerase Chain Reaction (PCR), Immunofluorescence Assays

Which Trends Are Contributing To Changes In The Influenza Diagnostic Market?

Major companies operating within the influenza diagnostic market are engaged in the development of innovative products, such as the Lucira COVID-19 & Flu Home Test, intended for simultaneous rapid qualitative detection. The Lucira COVID-19 and Flu Home Test functions as a single-use at-home testing kit, delivering results from self-collected nasal swab samples in approximately 30 minutes. For example, in February 2023, Pfizer Inc., a US-based pharmaceutical company, obtained approval for the Lucira COVID-19 & Flu Home Test. This test is capable of detecting both influenza A and B, commonly known as the flu, and SARS-CoV-2, the virus causing COVID-19.

Which Organizations Are Operating Within The Influenza Diagnostic Market?

Major companies operating in the influenza diagnostic market are F. Hoffmann-La Roche Ltd., Quidel Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Hologic Inc., Becton Dickinson and Company, DiaSorin SpA, Luminex Corporation, Meridian Bioscience Inc., GenMark Diagnostics Inc., SA Scientific Ltd., Sekisui Diagnostics LLC, bioMérieux Inc., Danaher Corporation, Siemens Healthineers AG, Coris Bioconcept Sprl, Mast Group, Elitech Technology lnc., Analytik Jena AG, altona Diagnostics GmbH, Tecan Trading AG, Genome Diagnostics Pvt Ltd., Germaine Laboratories Inc., Response Biomedical Corporation, TAUNS Laboratories Inc., TRUPCR Europe Ltd., Quest Diagnostics Inc., Labcorp Employer Services Inc.

Access The Complete Influenza Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

Which Regional Market Leads The Influenza Diagnostic Market?

North America was the largest region in the influenza diagnostics market in 2025. Western Europe was the second largest region in the influenza diagnostics market. The regions covered in the influenza diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Influenza Diagnostic Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=3237&type=smp

Browse Through More Reports Similar to the Global Influenza Diagnostic Market 2026, By The Business Research Company

Virtual Clinical Trials Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/virtual-clinical-trials-global-market-report

Clinical Trial Supplies Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-trial-supplies-global-market-report

Clinical Trial Management Systems Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-trial-management-systems-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795